Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Christina Lake CannabisCLCFF -8.93% Debt-to-EBITDA is 1.38 as of Nov. 2025. The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, Christina Lake Cannabis ranks better than 56.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Christina Lake Cannabis's Debt-to-EBITDA or its related term are showing as below:
CLCFF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.87 Med: -2.12 Max: 1.28
Current: 1.28
During the past 6 years, the highest Debt-to-EBITDA Ratio of Christina Lake Cannabis was 1.28. The lowest was -6.87. And the median was -2.12.
CLCFF's Debt-to-EBITDA is ranked better than 56.67% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs CLCFF: 1.28
Christina Lake Cannabis (OTCPK:CLCFF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Christina Lake Cannabis Debt-to-EBITDA Related Terms
Christina Lake Cannabis Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Christina Lake Cannabis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Christina Lake Cannabis Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Christina Lake Cannabis's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Christina Lake Cannabis's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Nov. 2025) EBITDA data.
Christina Lake Cannabis (CLCFF) has a Debt-to-EBITDA of 1.38 as of Nov. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Christina Lake Cannabis. According to the industry distribution chart, Christina Lake Cannabis ranks #299 out of 690 companies in the Drug Manufacturers industry, placing it in the top 43.3%.
Is Christina Lake Cannabis' Debt-to-EBITDA too high?
Christina Lake Cannabis' current Debt-to-EBITDA is 1.38. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Christina Lake Cannabis' value of 1.38 is 17.4% below this industry median. Based on the distribution chart, Christina Lake Cannabis ranks #299 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Christina Lake Cannabis' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Christina Lake Cannabis ranks #299 out of 690 companies for Debt-to-EBITDA. This puts Christina Lake Cannabis in the upper half of its industry. The industry median Debt-to-EBITDA is 1.67. Christina Lake Cannabis' value of 1.38 is 17.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Christina Lake Cannabis's current Debt-to-EBITDA of 1.38 is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Christina Lake Cannabis. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Christina Lake Cannabis's current Debt-to-EBITDA is 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Christina Lake Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Christina Lake Cannabis (CLCFF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.02 — trading 51.8% below its estimated fair value. The current Debt-to-EBITDA is 1.38 and 17.4% below the Drug Manufacturers industry median of 1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Christina Lake Cannabis (CLCFF), the current Debt-to-EBITDA is 1.38 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Christina Lake Cannabis Corp is a licensed producer of cannabis. The company cultivates cannabis using strains specifically developed for outdoor cultivation. It is a producer of high-quality, low-cost, sun-grown cannabis flowers, oil cannabinoids, and hemp-based extracts and derivatives, serving domestic and international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLCFF has been successfully added to your 
